-
Lipocine Showered With Good News Recently
Monday, October 10, 2016 - 10:14am | 417Read More...Shares of Lipocine Inc (NASDAQ: LPCN), a specialty pharmaceutical company that focuses on developing products in the are of men's and women's health, has seen its stock rise nearly 40 percent over the past two weeks. September 26: Positive Top-Line Results The company announced...
-
Supernus Up 3.7%, Federal Court Says Actavis Is Infringing On Patents
Monday, February 8, 2016 - 1:51pm | 233Read More...Supernus Pharmaceuticals Inc (NASDAQ: SUPN), a specialty pharmaceutical company that develops treatments for central nervous system diseases, were trading higher by more than 3 percent on Monday. Supernus Pharmaceuticals announced earlier in the morning that Judge Renee Marie Bumb of the United...
-
Here's Why Valeant Is Worrying Deutsche Bank And Morgan Stanley
Tuesday, November 17, 2015 - 12:19pm | 697Read More...Shares of Valeant Pharmaceuticals Intl Inc (NYSE: VRX) are now lower by 70 percent over the past three months. Analysts at Deutsche Bank and Morgan Stanley both raised concerns on the company's business. Gregg Gilbert of Deutsche Bank noted a propriety survey with doctors indicated...
-
Valeant Shares Fall Yet Again As Company Holds Conference Call To Defend Itself
Monday, October 26, 2015 - 8:37am | 427Read More...Shares of Valeant Pharmaceuticals Intl Inc (NYSE: VRX) were trading lower by more than 10 percent early Monday morning. The Wall Street Journal reported over the weekend that the relationship between Valeant and specialty pharmacies are "more intertwined than though." Valeant...
-
Northland Starts Jazz Pharma, Mallinckrodt, Shire With Outperform Ratings
Wednesday, October 14, 2015 - 9:36am | 531Read More...David Buck of Northland Capital Markets initiated coverage of Jazz Pharmaceuticals plc (NASDAQ: JAZZ), Mallinckrodt PLC (NYSE: MNK), and Shire PLC (ADR) (NASDAQ: SHPG) with Outperform ratings. Buck is positive on the long-term revenue prospect of the three names. Buck noted all three...
-
Stifel Reiterates Horizon Pharma As 'Select List' Pick, Sees 'Buying Opportunity In Multiple Misguided Reactions'
Wednesday, September 23, 2015 - 8:50am | 449Read More...Shares of Horizon Pharma PLC (NASDAQ: HZNP) have come under "inordinate pressure" in the last few days, according to Annabel Samimy of Stifel. Samimy maintained a Buy rating and $45 price target on the stock. According to Samimy, Horizon is "one of the stronger diversified...
